Sutro Biopharma, Inc. (NASDAQ: STRO) is a Healthcare company (Biotechnology) with a market capitalization of $148M. The Maz Rating grades it against the other companies in its sector.
Sutro Biopharma, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.92, Sutro Biopharma, Inc. trades at 3.3x sales. Over the last twelve months it generated about $45M of revenue and a net loss of $209M. It runs a gross margin of 94.4%, an operating margin of -255.2% and a net margin of -344.2%. It shows return on equity of 142.7%, return on invested capital of -88.5% and a free cash flow yield of -87.6%. On the balance sheet: a debt-to-equity ratio of -1.95 and a current ratio of 2.94. Over the past 52 weeks the share price ranged from $7.15 to $43.85, with a beta of 1.55.
Sutro Biopharma, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 18 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Sutro Biopharma, Inc. (STRO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 102.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 58.2% / 30% · Interest income / Revenue 16.1% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 102.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 58.2% / 33% · Receivables / Mkt Cap (36m) 5.25% / 49% · Interest income / Revenue 16.1% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 102.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 58.2% / 33.33% · Receivables / Mkt Cap (24m) 5.25% / 33.33% · Interest income / Revenue 16.1% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 60.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 82.7% / 33.33% · Receivables / Avg Assets (4Q) 4.46% / 33.33% · Interest income / Revenue 16.1% / 5% | Fail |
| FTSE | Debt / Total Assets 141.1% / 33.33% · (Cash+ST Inv) / Total Assets 80.5% / 33.33% · (Cash+Recv) / Total Assets 87.7% / 33.33% · Interest income / Revenue 16.1% / 5% | Fail |
No. As of September 2026, Sutro Biopharma, Inc. (STRO) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Sutro Biopharma, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m), (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 16.1% of each dividend: Sutro Biopharma, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.